T1D Fund
Edit

T1D Fund

http://www.t1dfund.org
Last activity: 02.05.2025
Active
Invests in categories: BioTechMedTechPlatformDevelopmentHealthTechDeliveryTechnologyDrugHardwareHuman
Portfolio
35
Persons
7
Mentions
25
Employees: 1-10
Investment Stage: Seed; Series A; Series B

Portfolio 35

DateNameWebsiteTotal RaisedLocation
22.09.2024Jaguar Gen...jaguargenetherapy.com-United Sta...
22.09.2024Cour Pharm...courpharma.com$135MUnited Sta...
22.09.2024Sab Biothe...sab.bio-United Sta...
22.09.2024Orizuru Th...orizuru-therapeutics.com--
22.09.2024Eledon Pha...eledon.com-United Sta...
10.03.2024Sana Biote...sana.com$2.79BUnited Sta...
10.03.2024vTv Therap...vtvtherapeutics.com-United Sta...
10.05.2023DiogenXdiogenx.com$35.2MFrance, Pr...
02.08.2022Egle Thera...egle-tx.com$10.54MFrance, Il...
13.08.2021GentiBiogentibio.com$177MUnited Sta...
Show more

Persons 7

DateFirst NameLast NameTitleLinkedInLocation
-MattWilliamsDirector o...-
-ClayRowlandAssociatelinkedin.c...-
-NandanPadukone-linkedin.c...-
-SeanO'ConnorPrincipal-
-KatieElliasManaging D...linkedin.c...-
-YuryKukushkin-linkedin.c...-
-WilliamOrentAssociatelinkedin.c...-

Mentions in press and media 25

DateTitleDescription
03.05.2025Zucara Therapeutics Secures $25 Million to Combat Diabetes ComplicationsZucara Therapeutics is on a mission. The Toronto-based company is tackling a significant challenge in diabetes management: hypoglycemia. Recently, Zucara completed its Series B financing, raising a total of $25 million. This funding is a li...
02.05.2025Zucara Therapeutics: $25 Million Series B Closed For Diabetes Life Sciences PlatformZucara Therapeutics – a diabetes life sciences company developing ZT-01, which is the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes – announced that it has completed the second and f...
01.05.2025Zucara Therapeutics Raises $5M in Second and Final Closing of US$25M Series B FinancingZucara Therapeutics Inc., a Toronto, Canada-based diabetes life sciences company, raised $US5m in the second and final closing of its US$25m Series B financing. The T1D Fund: A Breakthrough T1D Venture, and other new investors invested a co...
19.03.2025Egle Therapeutics Secures €9.3 Million to Advance Immuno-Oncology ResearchEgle Therapeutics is on the rise. The Paris-based biotechnology company has just secured €9.3 million in state funding. This investment comes from the French government’s France 2030 initiative, specifically under the “Innovations in Biothe...
18.03.2025Egle Therapeutics: €9.3 Million In State Funding Raised To Develop Therapies Targeting Regulatory T CellsEgle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, announced that it secured €9.3 million in state funding under the Innovations i...
09.01.2025Aspect Biosystems Raises US$115M in Series B FinancingAspect Biosystems, a Vancouver, BC, Canada-based biotechnology company developing bioprinted tissue therapeutics for the regenerative medicine, raised US$115M in Series B funding. The round was led by Dimension, with participation from exis...
25.06.2024Breakthrough T1D-Funded Research Featured at American Diabetes Association 84th Scientific SessionsNEW YORK, June 25, 2024 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, gathered with researchers, diabetes professionals, and other leaders in T1D at the America...
28.02.2024vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund-
24.10.2023Former Novo Nordisk Executive, Dr. Todd Hobbs, joins Diasome Pharmaceuticals as Chief Medical OfficerDr. Todd Hobbs, Former North American Chief Medical Officer at Novo Nordisk, to Guide Diasome's HDV Platform Expansion The Fund is proud to work alongside the company’s management team – including Dr. Hobbs – as they advance their high impa...
11.05.2023Biotech startup DiogenX secures €27.5M to develop therapeutic solutions for Type 1 diabetesMarseille-based DiogenX, a preclinical-stage biotech company specialising in the development of pancreatic beta-cell modulators for the treatment of diabetes, announced on Wednesday, May 10, that it has raised €27.5M in a Series A round of ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In